"Abatacept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.
| Descriptor ID |
D000069594
|
| MeSH Number(s) |
D12.776.124.790.651.114.580.225 D12.776.377.715.548.114.580.225
|
| Concept/Terms |
CTLA-4-Ig- CTLA-4-Ig
- Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin
- Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin
- CTLA4-Ig
- CTLA4-Ig Immunoconjugate
- CTLA4 Ig Immunoconjugate
- Immunoconjugate, CTLA4-Ig
- CTLA4-Fc
|
Below are MeSH descriptors whose meaning is more general than "Abatacept".
Below are MeSH descriptors whose meaning is more specific than "Abatacept".
This graph shows the total number of publications written about "Abatacept" by people in this website by year, and whether "Abatacept" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Abatacept" by people in Profiles.
-
Abatacept-based Graft-Versus-Host Disease Prophylaxis in Haplo-identical Hematopoietic Cell Transplant in a High-risk Cohort. J Pediatr Hematol Oncol. 2022 10 01; 44(7):383-387.
-
An open-label study evaluating the efficacy of abatacept in alopecia areata. J Am Acad Dermatol. 2021 Mar; 84(3):841-844.
-
Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther. 2015 Jun 13; 17:159.
-
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014 Feb; 66(2):379-89.
-
Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep. 2011 Aug; 13(4):308-16.
-
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct; 62(10):3077-87.